Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasminapant (APG-1387) Phase I in Advanced Solid Tumors/Hematologic Malignancies
NCT03386526Phase 1Completed
- Sponsor
- Ascentage Pharma
- Start
- Nov 2017
- Primary completion
- Oct 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasminapant in solid tumor and hematologic malignancy, sponsored by Ascentage Pharma. Primary endpoint: Maximum Tolerated Dose. Started Nov 2017; status: completed.
02
Drugs
dasminapant
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT03386526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386526.